Gujarat Themis Acquires MicroBiopharm Japan for ₹1,300 Crore
Gujarat Themis Biosyn Limited will acquire 100% of Japan's MicroBiopharm Japan for ₹1,300 Crores. The deal, funded by debt and equity, aims to enhance GTBL's CDMO capabilities. The acquisition is expected to close in Q2 FY2027, subject to regulatory approvals.
The acquisition of a 100% stake in a company with significant revenue and specialized capabilities like MBJ represents a major strategic move that will likely have a substantial impact on Gujarat Themis Biosyn Limited's business operations, market position, and future growth trajectory.
The acquisition of a strategic target like MicroBiopharm Japan, with its established capabilities and revenue, is a positive development for Gujarat Themis Biosyn Limited, aligning with its long-term growth strategy and expansion into the CDMO sector.
Gujarat Themis Biosyn Limited (GTBL) has entered into a definitive agreement to acquire 100% equity shareholding of MicroBiopharm Japan Co., Ltd. (MBJ), a Japanese pharmaceutical company, through its wholly-owned subsidiary, Themis Biosyn Japan Limited. This strategic acquisition is subject to approvals and customary closing formalities.
MBJ is a Japan-based pharmaceutical company specializing in research, development, and manufacturing of APIs, intermediates, and offering CDMO services. It possesses strong capabilities in microbial fermentation and biotechnology, with a portfolio including oncology APIs, plasmid DNA manufacturing, ADC conjugation, and enzyme-based bioconversion platforms. For FY 2026E, MBJ reported an estimated revenue of JPY 9.5 Billion (approximately ₹570 Crores).
The acquisition represents a significant step in GTBL's strategy to transition from a fermentation-led intermediates business to a technology-driven CDMO platform. The total consideration for the acquisition is JPY 21.5 Billion (approximately ₹1,300 Crores), which will be funded through a mix of debt and equity. Approvals required include those under Japan's Foreign Exchange and Foreign Trade Act (FEFTA) and other regulatory requirements.
The transaction is anticipated to close in Q2 FY2027, contingent upon the satisfaction of customary closing conditions and receipt of necessary regulatory approvals. The acquisition is not a related party transaction. MBJ has a history of revenues including JPY 7,827 Million (approx. ₹470 Crores) in FY23, JPY 9,741 Million (approx. ₹580 Crores) in FY24, and JPY 9,312 Million (approx. ₹560 Crores) in FY25.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.